MARTINSRIED, Germany, June 23, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR.F - News) (Prime Standard Segment:TecDAX) announced an expansion of its existing therapeutic antibody collaboration with Novartis. The original collaboration agreement provided for a three-year term with an option for Novartis to extend. The collaboration will now go through May 2011. In light of the expanded collaboration, MorphoSys is currently reviewing the status of its financial guidance 2006 and will provide an update latest by July 28, 2006, the presentation of its Q2 results.
